Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020–2025: a real-world retrospective study from a reference centre
Randomized trials have demonstrated that nintedanib is beneficial for Systemic Sclerosis-associated interstitial lung disease (SSc-ILD) with an acceptable safety profile. We evaluated the long-term safety and efficacy of nintedanib in a real-world SSc-ILD cohort. Medical records…